HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#98 / 98 Total
NLSP - NLS Pharmaceutics Ltd - Stock Price Chart
TickerNLSP [NASD]
CompanyNLS Pharmaceutics Ltd
CountrySwitzerland
IndustryBiotechnology
Market Cap8.78MEPS (ttm)-2.63
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y33.06%
P/S-EPS next 5Y-
P/B-EPS Q/Q87.78%
Dividend-Sales Q/Q-
Insider Own42.10%Inst Own4.78%
Insider Trans0.00%Inst Trans0.37%
Short Float3.18%Earnings-
Analyst Recom3.00Target Price160.00
Avg Volume289.35K52W Range1.30 - 15.59
Jun-30-25 07:00AM NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing (PR Newswire)
Jun-16-25 07:00AM NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
May-21-25 07:30AM NLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual Meeting (PR Newswire)
Apr-15-25 09:00AM NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models (PR Newswire)
Mar-31-25 09:10AM NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement (ACCESSWIRE) +18.46%
Mar-10-25 07:00AM NLS Pharmaceutics CEO Issues Letter to Shareholders (PR Newswire)
Feb-27-25 07:00AM NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform (PR Newswire)
Feb-25-25 09:05AM Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment (PR Newswire)
Feb-10-25 07:30AM NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies (PR Newswire) +37.43%
Jan-31-25 07:30AM Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics (PR Newswire) +25.76%
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of neurobehavioral and neurocognitive disorders. Its product portfolio includes Quilience, a treatment for excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol, a treatment for attention deficit hyperactivity disorder. The company was founded by Ronald Hafner, Eric Konofal, and Alexander Zwyer on June 10, 2015 and is headquartered in Zurich, Switzerland.
12345678910
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.